Home
HelpTest Code LS3 Lymphocyte Subset 3
Specimen and Container/Tube
Specimen Type: Whole blood
Preferred Specimen: lavender top
Other Acceptable specimens: not applicable
Specimen Stability
|
Storage Temperature |
Stability |
|
Room temperature (20 - 25°C) |
24 hours |
|
Refrigerated (2 - 10°C) |
not acceptable |
|
Frozen (-20°C) |
not acceptable |
Collection Instructions
Collect specimen per standard laboratory collection procedures.
Specimen Handling and Transport Instructions
UCMC Onsite Instructions: Collect specimen per standard collection procedure and send to laboratory immediately.
UCMC Offsite and UC MedLab Outreach Instructions: Collect specimen per standard collection procedure and send to laboratory immediately. Specimens must be received within 24 hours. If transport is delayed, retain specimen at room temperature.
Rejection Criteria
- Common specimen rejected situations include: incorrect specimen type, insufficient volume, missing or incomplete specimen identifiers, incorrect specimen transport, or specimens outside stability limits.
- Frozen or heated specimens will be rejected
- Clotted or quantity not sufficient specimens are not suitable for testing and will be rejected
Reference Values
|
Analyte |
Age |
Sex |
Reference Range |
|
Absolute lymphocyte count |
3 months |
Male and female |
3400 – 7600 |
|
Absolute lymphocyte count |
6 months |
Male and female |
3900 – 9000 |
|
Absolute lymphocyte count |
1 year |
Male and female |
3400 – 9000 |
|
Absolute lymphocyte count |
2 years |
Male and female |
3600 – 8900 |
|
Absolute lymphocyte count |
6 years |
Male and female |
2300 – 5400 |
|
Absolute lymphocyte count |
12 years |
Male and female |
1900 – 3700 |
|
Absolute lymphocyte count |
12 years and up |
Male and female |
1200 – 3265 |
|
CD3 percent |
3 months |
Male and female |
53 – 84 |
|
CD3 percent |
6 months |
Male and female |
51 – 77 |
|
CD3 percent |
1 year |
Male and female |
49 – 76 |
|
CD3 percent |
2 years |
Male and female |
53 – 75 |
|
CD3 percent |
6 years |
Male and female |
56 – 75 |
|
CD3 percent |
12 years |
Male and female |
60 – 76 |
|
CD3 percent |
12 years and up |
Male and female |
61 – 82 |
|
CD3 absolute count |
3 months |
Male and female |
2500 – 5500 |
|
CD3 absolute count |
6 months |
Male and female |
2500 – 5600 |
|
CD3 absolute count |
1 year |
Male and female |
1900 – 5900 |
|
CD3 absolute count |
2 years |
Male and female |
2100 – 6200 |
|
CD3 absolute count |
6 years |
Male and female |
1400 – 3700 |
|
CD3 absolute count |
12 years |
Male and female |
1200 – 2600 |
|
CD3 absolute count |
12 years and up |
Male and female |
828 – 2328 |
|
CD4 percent |
3 months |
Male and female |
35 – 64 |
|
CD4 percent |
6 months |
Male and female |
35 – 56 |
|
CD4 percent |
1 year |
Male and female |
31 – 56 |
|
CD4 percent |
2 years |
Male and female |
32 – 51 |
|
CD4 percent |
6 years |
Male and female |
28 – 47 |
|
CD4 percent |
12 years |
Male and female |
31 - 47 |
|
CD4 percent |
12 years and up |
Male and female |
35 – 60 |
|
CD4 absolute count |
3 months |
Male and female |
1600 – 4000 |
|
CD4 absolute count |
6 months |
Male and female |
1800 – 4000 |
|
CD4 absolute count |
1 year |
Male and female |
1400 – 4300 |
|
CD4 absolute count |
2 years |
Male and female |
1300 – 4300 |
|
CD4 absolute count |
6 years |
Male and female |
700 – 2220 |
|
CD4 absolute count |
12 years |
Male and female |
650 – 1500 |
|
CD4 absolute count |
12 years and up |
Male and female |
515 – 1642 |
|
CD8 percent |
3 months |
Male and female |
12 – 28 |
|
CD8 percent |
6 months |
Male and female |
12 – 23 |
|
CD8 percent |
1 year |
Male and female |
12 – 24 |
|
CD8 percent |
2 years |
Male and female |
14 – 30 |
|
CD8 percent |
6 years |
Male and female |
16 – 30 |
|
CD8 percent |
12 years |
Male and female |
18 – 35 |
|
CD8 percent |
12 years and up |
Male and female |
14 – 38 |
|
CD8 absolute count |
3 months |
Male and female |
560 – 1700 |
|
CD8 absolute count |
6 months |
Male and female |
590 – 1600 |
|
CD8 absolute count |
1 year |
Male and female |
500 – 1700 |
|
CD8 absolute count |
2 years |
Male and female |
620 – 2000 |
|
CD8 absolute count |
6 years |
Male and female |
490 – 1300 |
|
CD8 absolute count |
12 years |
Male and female |
370 – 1100 |
|
CD8 absolute count |
12 years and up |
Male and female |
212 – 887 |
|
CD19 percent |
3 months |
Male and female |
6 – 32 |
|
CD19 percent |
6 months |
Male and female |
11 – 41 |
|
CD19 percent |
1 year |
Male and female |
14 – 37 |
|
CD19 percent |
2 years |
Male and female |
16 – 35 |
|
CD19 percent |
6 years |
Male and female |
14 – 33 |
|
CD19 percent |
12 years |
Male and female |
13 – 27 |
|
CD19 percent |
12 years and up |
Male and female |
6 – 22 |
|
CD19 absolute count |
3 months |
Male and female |
300 – 2000 |
|
CD19 absolute count |
6 months |
Male and female |
430 – 3000 |
|
CD19 absolute count |
1 year |
Male and female |
610 – 2600 |
|
CD19 absolute count |
2 years |
Male and female |
720 – 2600 |
|
CD19 absolute count |
6 years |
Male and female |
390 – 1400 |
|
CD19 absolute count |
12 years |
Male and female |
270 – 860 |
|
CD19 absolute count |
12 years and up |
Male and female |
103 – 581 |
|
CD56 percent |
3 months |
Male and female |
4 – 18 |
|
CD56 percent |
6 months |
Male and female |
3 – 14 |
|
CD56 percent |
1 year |
Male and female |
3 – 15 |
|
CD56 percent |
2 years |
Male and female |
3 – 15 |
|
CD56 percent |
6 years |
Male and female |
4 – 17 |
|
CD56 percent |
12 years |
Male and female |
4 – 17 |
|
CD56 percent |
12 years and up |
Male and female |
1 – 21 |
|
CD56 absolute count |
3 months |
Male and female |
170 – 1100 |
|
CD56 absolute count |
6 months |
Male and female |
170 – 830 |
|
CD56 absolute count |
1 year |
Male and female |
160 – 950 |
|
CD56 absolute count |
2 years |
Male and female |
180 – 920 |
|
CD56 absolute count |
6 years |
Male and female |
130 – 720 |
|
CD56 absolute count |
12 years |
Male and female |
100 – 480 |
|
CD56 absolute count |
12 years and up |
Male and female |
20 – 360 |
|
CD4:CD8 Ratio |
3 months |
Male and female |
1.3 – 5.3 |
|
CD4:CD8 Ratio |
6 months |
Male and female |
1.5 – 4.7 |
|
CD4:CD8 Ratio |
1 year |
Male and female |
1.3 – 4.7 |
|
CD4:CD8 Ratio |
2 years |
Male and female |
1.1 – 3.6 |
|
CD4:CD8 Ratio |
6 years |
Male and female |
0.9 – 2.9 |
|
CD4:CD8 Ratio |
12 years |
Male and female |
0.9 – 4.3 |
|
CD4:CD8 Ratio |
12 years and up |
Male and female |
0.9 – 3.3 |
Critical Values
not applicable
Clinical Indications
- Assessing the status of the lymphoid immune system in patients with primary immunodeficiencies
- Comprehensive Immune Monitoring
- Immune Reconstitution
Test Components
Absolute lymphocyte count, CD3 percent, CD3 absolute count, CD4 percent, CD4 absolute count, CD8 percent, CD8 absolute count, CD4:CD8 ratio, CD19 percent, CD19 absolute count, CD56 percent, CD56 absolute count, CD16 percent, CD16 absolute count, CD3+CD4+CD25+ percent, CD3+CD4+CD25+ absolute count, CD3+CD8+CD25+ percent, CD3+CD8+CD25+ absolute count, CD3+CD4+CD45RA+ percent, CD3+CD4+CD45RA+ absolute count, CD3+CD4+CD45RO+ percent, CD3+CD4+CD45RO+ absolute count, CD1 percent, CD1 absolute, CD5 percent, CD5 absolute count, HLADR percent, and HLADR absolute
Methodology
Flow cytometry
CPT Codes
86355, 86356 x8, 86360, 86359
LOINC Codes
ABLY 30364-4, CD 33719-6
Volume
Preferred Volume: 4.0 mL
Minimum Volume: 1.0 mL
Turnaround Time
Turnaround times are relative to the time the specimen is received in the test laboratory.
STAT Turnaround Time: not available
Routine Turnaround Time: 24 hours
Testing Schedule: Monday - Friday 8:00 am - 5:00 pm and Saturday 8:00 am - 3:00 pm
Synonyms/Search Keywords
Primary immunodeficiency panel, T, B, NK, Native T, Comprehensive Immune Monitoring, Immune Reconstitution
Last Reviewed Date
8/12/2024